Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €0.72 EUR
Change Today +0.012 / 1.70%
Volume 3.1K
PTNA On Other Exchanges
Symbol
Exchange
NYSE Amex
Frankfurt
As of 3:06 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

palatin technologies inc (PTNA) Snapshot

Open
€0.71
Previous Close
€0.70
Day High
€0.75
Day Low
€0.71
52 Week High
06/5/15 - €1.45
52 Week Low
11/4/14 - €0.42
Market Cap
40.9M
Average Volume 10 Days
5.3K
EPS TTM
--
Shares Outstanding
57.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PALATIN TECHNOLOGIES INC (PTNA)

palatin technologies inc (PTNA) Related Bloomberg News

View More Bloomberg News

palatin technologies inc (PTNA) Related Businessweek News

No Related Businessweek News Found

palatin technologies inc (PTNA) Details

Palatin Technologies, Inc., a biopharmaceutical company, develops peptide therapeutics for the treatment of diseases. The company’s clinical development product is Bremelanotide, a peptide melanocortin receptor agonist that has completed Phase 2B clinical trial for the treatment of female sexual dysfunction (FSD). Its drug development programs include Melanocortin receptor-1 agonist peptides for the treatment of inflammatory and dermatologic disease indications; Next Generation Melanocortin receptor-4 peptide agonists, which is in preclinical trials for the treatment of erectile dysfunction; and PL-3994, a natriuretic peptide receptor-A agonist that has completed Phase I clinical trial for the treatment of cardiovascular and pulmonary indications, as well as other melanocortin programs. The company has a license, co-development, and commercialization agreement with Gedeon Richter Plc to commercialize Bremelanotide for FSD in Europe and selected countries; and research collaboration and license agreement with AstraZeneca AB to discover, develop, and commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes, and related metabolic syndrome. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.

Founded in 1986

palatin technologies inc (PTNA) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $450.0K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $410.0K
Compensation as of Fiscal Year 2014.

palatin technologies inc (PTNA) Key Developments

Palatin Technologies Seeks Acquistions

Palatin Technologies Inc. (AMEX:PTN) is looking for acquisitions. Palatin Technologies intends to use the net proceeds from the sale of securities for general corporate purposes, including capital expenditures. From time to time, we evaluate the possibility of acquiring businesses, products and technologies, and we may use a portion of the proceeds as consideration for acquisitions. Until we use net proceeds for these purposes, we may invest them in interest-bearing securities.

Palatin Technologies Inc. Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-12-2015 11:00 AM

Palatin Technologies Inc. Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-12-2015 11:00 AM. Venue: InterContinental Boston, 510 Atlantic Avenue, Boston, MA 02210, United States.

Palatin Technologies Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended March 31, 2015

Palatin Technologies Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended March 31, 2015. For the quarter, the company's loss from operations was $8,722,391 compared to $3,363,738 a year ago. Loss before income taxes was $9,150,538 compared to $3,359,557 a year ago. Net loss was $9,150,538 compared to $1,512,911 a year ago. Basic and diluted net loss per common share was $0.07 compared to $0.01 a year ago. The increase in net loss for the quarter ended March 31, 2015 compared to the same period last fiscal year was attributable to the increase in research and development expenses related to Phase 3 reconnectstudy with bremelanotide for the treatment of FSD. For the nine months, the company's loss from operations was $5,505,865 compared to $11,466,826 a year ago. Loss before income taxes was $6,110,584 compared to $11,455,200 a year ago. Net loss was $5,579,076 compared to $9,608,554 a year ago. Basic and diluted net loss per common share was $0.05 compared to $0.09 a year ago. Contract revenues were $12,951,730.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PTNA:GR €0.72 EUR +0.012

PTNA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PTNA.
View Industry Companies
 

Industry Analysis

PTNA

Industry Average

Valuation PTNA Industry Range
No financial data is available for PTNA.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PALATIN TECHNOLOGIES INC, please visit www.palatin.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.